WATERTOWN, Mass.–(BUSINESS WIRE)–Oct 23, 2020–
SQZ Biotechnologies (SQZ), a clinical-stage biotechnology firm creating transformative cell therapies for sufferers with most cancers, infectious illnesses and different critical circumstances, right this moment introduced the appointments of Marc Schegerin, MD and Sapna Srivastava, PhD to its board of administrators in addition to Micah Zajic as chief enterprise officer.
“It’s an honor to have Marc and Sapna be part of our board of administrators. Their senior management expertise within the biotech and healthcare fields will likely be invaluable as we proceed to execute on our long-term imaginative and prescient to create novel, impactful cell therapies for sufferers in want,” stated Armon Sharei, PhD, founder and chief government officer of SQZ. “As well as, I’m happy to welcome Micah to our crew throughout this pivotal time in our evolution. His various expertise in biotech and company finance will present us with strategic perception and powerful management as we proceed to develop our pipeline and handle our strategic partnerships.”
Dr. Schegerin joins the SQZ board of administrators with a wealth of expertise within the healthcare and monetary industries. He’s at the moment chief monetary officer and chief working officer at Morphic Therapeutics. Earlier than becoming a member of Morphic, Dr. Schegerin served as chief monetary officer, and head of technique at ArQule, till its acquisition by Merck for $2.7 billion. Previous to ArQule, Dr. Schegerin served in varied senior healthcare funding banking roles at CitiGroup, Financial institution of America Merrill Lynch, and Goldman Sachs. Dr. Schegerin has additionally held business administration roles at Biogen and Sage Therapeutics. Dr. Schegerin earned his MD from Dartmouth Medical Faculty (Payson/Hampers Scholar) and his MBA from the Tuck Faculty of Enterprise at Dartmouth (Don Wilson, III scholar).
Dr. Srivastava was most just lately the chief monetary and technique officer for Abide Therapeutics, which was acquired by Lundbeck. Beforehand Dr. Srivastava served as chief monetary and technique officer for Intellia, the place she performed an integral function in launching the corporate’s monetary operations and strategic course and spearheading its preliminary public providing. Moreover, Dr. Srivastava has practically 15 years of expertise as a analysis analyst within the biotechnology sector, which incorporates her work at Goldman Sachs, Morgan Stanley, ThinkEquity Companions, and JP Morgan. Dr. Srivastava additionally has expertise as an impartial board member and advisor to a number of biotechnology corporations and non-profit organizations. Dr. Srivastava obtained her PhD in neuroscience from New York College and her bachelors from St. Xavier’s Faculty in India.
“We’re thrilled to have each Dr. Schegerin and Dr. Srivastava be part of our board,” stated Amy Schulman, chair of the board of administrators at SQZ. “Each have various expertise inside the biotechnology business and have demonstrated success throughout the spectrum of each finance and healthcare, which bolsters our board’s experience as we navigate the corporate’s subsequent section of development.”
Micah Zajic joins SQZ as chief enterprise officer with over 15 years of expertise in biotech and company improvement. He most just lately served as vp of company improvement at MeiraGTx and was answerable for all enterprise improvement actions. Previous to MeiraGTx, Mr. Zajic labored at Alexion Prescription drugs, the place he was primarily centered on the analysis and execution of exterior partnerships, license agreements, and acquisitions. He began his profession in Morgan Stanley’s International Capital Markets and Healthcare Funding Banking Group. Mr. Zajic obtained his bachelors in economics from Georgetown College.
About SQZ Biotech
SQZ Biotech is a clinical-stage biotechnology firm creating transformative cell therapies for sufferers with most cancers, infectious illnesses, and different critical circumstances. Utilizing its proprietary expertise, SQZ has the distinctive capability to ship a number of supplies into many affected person cell sorts to engineer what we imagine to be an unprecedented vary of potential therapeutics for a spread of illnesses. SQZ has the potential to create well-tolerated cell therapies that may present therapeutic profit for sufferers and doubtlessly enhance the affected person expertise over current cell remedy approaches, with accelerated manufacturing timelines beneath 24 hours and the elimination of pre-conditioning and prolonged hospital stays. Our purpose is to make use of the SQZ method to ascertain a brand new paradigm for cell therapies. The primary therapeutic purposes leverage SQZ’s capability to generate target-specific immune responses, each in activation for the therapy of stable tumors and immune tolerance for the therapy of undesirable immune reactions and autoimmune illnesses. For extra data please go to www.sqzbiotech.com.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20201023005055/en/
617-758-8672 ext. 728
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES HEALTH CLINICAL TRIALS ONCOLOGY
SOURCE: SQZ Biotechnologies
Copyright Enterprise Wire 2020.
PUB: 10/23/2020 08:00 AM/DISC: 10/23/2020 08:01 AM
Copyright Enterprise Wire 2020.